US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Nektar Therapeutics - Common Stock
(NQ:
NKTR
)
42.22
-1.36 (-3.12%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nektar Therapeutics - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday
↗
April 20, 2026
Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.
Via
Benzinga
These stocks are gapping in today's session
↗
April 20, 2026
Via
Chartmill
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 20, 2026
From
Schall Law
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 16, 2026
From
Schall Law
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
April 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
April 14, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 13, 2026
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
April 09, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 09, 2026
From
Schall Law
Via
GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) DEADLINE ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
April 09, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
April 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
April 07, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 06, 2026
From
Schall Law
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
April 03, 2026
From
Schall Law
Via
GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
April 02, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NKTR SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
April 02, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky
March 31, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
March 31, 2026
From
Pomerantz LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 31, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
March 31, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
NEKTAR CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm
March 27, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
NEKTAR THERAPEUTICS (NKTR) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Nektar Therapeutics Investors of Upcoming Deadline
March 26, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
March 25, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
March 25, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky
March 24, 2026
From
Levi & Korsinsky, LLP
Via
Business Wire
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers – NKTR
March 24, 2026
From
Pomerantz LLP
Via
GlobeNewswire
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
March 24, 2026
From
Schall Law
Via
GlobeNewswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Nektar Therapeutics (NKTR)
March 24, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
March 23, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
March 20, 2026
From
Glancy Prongay Wolke & Rotter LLP
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
